Inatherys is a biotechnology company focused on developing monoclonal antibodies aimed at treating advanced cancers and severe inflammatory diseases. Their lead products, INA03 and INA02, target specific receptors involved in these conditions. INA03 is designed to target the transferrin receptor (CD71), which is highly expressed on tumor cells with significant proliferative capacity, allowing for preferential targeting of cancer cells. Meanwhile, INA02 is an anti-CD89 antibody that acts on inflammatory cells, binding to the CD89 receptor to mitigate the release of inflammatory mediators before an inflammatory response occurs. Both antibodies have shown promise in preclinical studies and are intended for patients with advanced stages of disease where conventional treatments have failed.

Founded in 2009 as a spin-off from INSERM, Inatherys leverages a team of experienced researchers and medical professionals with extensive backgrounds in onco-hematology and pharmaceutical development. The company’s mission is to address significant public health issues posed by cancers and severe inflammatory diseases, which affect millions globally. With a strong foundation in academic research and a commitment to innovation, Inatherys aims to provide effective therapeutic solutions through its monoclonal antibody development efforts.

France

INATHERYS is a biotechnology company that specializes in precision drug delivery systems for treating proliferative cancers through innovative ADC technology targeting CD71.

Inatherys

Company Details